PubRank

Mark I Greene

Author PubWeight™ 91.25‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007 6.61
2 Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 2007 6.22
3 FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc Natl Acad Sci U S A 2007 3.32
4 Development of Foxp3(+) regulatory t cells is driven by the c-Rel enhanceosome. Immunity 2009 2.84
5 ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007 2.78
6 Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov 2009 2.00
7 CD147 immunoglobulin superfamily receptor function and role in pathology. Exp Mol Pathol 2007 1.77
8 TGF-beta and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc Natl Acad Sci U S A 2008 1.65
9 Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet 2010 1.56
10 FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease. Int Immunol 2007 1.39
11 Characterization of the structures involved in localization of the SUN proteins to the nuclear envelope and the centrosome. DNA Cell Biol 2006 1.26
12 Histone acetyltransferase mediated regulation of FOXP3 acetylation and Treg function. Curr Opin Immunol 2010 1.23
13 Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp Mol Pathol 2009 1.22
14 FOXP3 actively represses transcription by recruiting the HAT/HDAC complex. Cell Cycle 2007 1.22
15 Structure of Sad1-UNC84 homology (SUN) domain defines features of molecular bridge in nuclear envelope. J Biol Chem 2011 1.22
16 Disabling receptor ensembles with rationally designed interface peptidomimetics. J Biol Chem 2002 1.21
17 The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol 2009 1.18
18 FOXP3 ensembles in T-cell regulation. Immunol Rev 2006 1.15
19 Structural and biological features of FOXP3 dimerization relevant to regulatory T cell function. Cell Rep 2012 1.14
20 FOXP3 and its partners: structural and biochemical insights into the regulation of FOXP3 activity. Immunol Res 2008 1.10
21 Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma. J Immunother 2009 1.10
22 Polymersomes: a new multi-functional tool for cancer diagnosis and therapy. Methods 2008 1.09
23 EGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway. Exp Mol Pathol 2005 1.09
24 Immune regulation by histone deacetylases: a focus on the alteration of FOXP3 activity. Immunol Cell Biol 2011 1.08
25 Structural insights into SUN-KASH complexes across the nuclear envelope. Cell Res 2012 1.07
26 Ca(2+) and K(+) (BK) channels in chick hair cells are clustered and colocalized with apical-basal and tonotopic gradients. J Physiol 2004 1.06
27 A sensitive and high-throughput assay to detect low-abundance proteins in serum. Nat Med 2006 1.03
28 Fish otolith contains a unique structural protein, otolin-1. Eur J Biochem 2002 1.01
29 The centrosome in normal and transformed cells. DNA Cell Biol 2004 1.00
30 UXT is a novel centrosomal protein essential for cell viability. Mol Biol Cell 2005 0.99
31 The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma. Exp Mol Pathol 2010 0.99
32 Gefitinib-sensitive EGFR lacking residues 746-750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis. DNA Cell Biol 2007 0.98
33 Human glucocorticoid-induced TNF receptor ligand regulates its signaling activity through multiple oligomerization states. Proc Natl Acad Sci U S A 2008 0.94
34 Biochemistry and therapeutic implications of mechanisms involved in FOXP3 activity in immune suppression. Curr Opin Immunol 2007 0.94
35 The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer. Cancer Discov 2012 0.94
36 Structural and biochemical studies of RIG-I antiviral signaling. Protein Cell 2012 0.93
37 Structural basis for ligand-mediated mouse GITR activation. Proc Natl Acad Sci U S A 2008 0.92
38 Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker. Proc Natl Acad Sci U S A 2009 0.91
39 Mechanisms of resistance to ErbB-targeted cancer therapeutics. J Clin Invest 2008 0.90
40 Nek2 targets the mitotic checkpoint proteins Mad2 and Cdc20: a mechanism for aneuploidy in cancer. Exp Mol Pathol 2009 0.90
41 Targeting erbB receptors. Semin Cell Dev Biol 2010 0.90
42 DIPA, which can localize to the centrosome, associates with p78/MCRS1/MSP58 and acts as a repressor of gene transcription. Exp Mol Pathol 2006 0.90
43 FOXP3+ regulatory T cell development and function require histone/protein deacetylase 3. J Clin Invest 2015 0.89
44 Role of extracellular subdomains of p185c-neu and the epidermal growth factor receptor in ligand-independent association and transactivation. Proc Natl Acad Sci U S A 2003 0.89
45 Histone deacetylase inhibitors and transplantation. Curr Opin Immunol 2007 0.87
46 Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107. Proc Natl Acad Sci U S A 2005 0.86
47 Special regulatory T-cell review: FOXP3 biochemistry in regulatory T cells--how diverse signals regulate suppression. Immunology 2008 0.86
48 Structural insights into the down-regulation of overexpressed p185(her2/neu) protein of transformed cells by the antibody chA21. J Biol Chem 2011 0.85
49 Expression and function of ErbB receptors and ligands in the pituitary. Endocr Relat Cancer 2011 0.84
50 Targeted antireceptor therapy with monoclonal antibodies leads to the formation of inactivated tetrameric forms of ErbB receptors. J Immunol 2007 0.84
51 Characterization of Su48, a centrosome protein essential for cell division. Proc Natl Acad Sci U S A 2006 0.84
52 Cooperative regulatory events and Foxp3 expression. Nat Immunol 2011 0.84
53 Sialylation regulates peripheral tolerance in CD4+ T cells. Int Immunol 2005 0.83
54 Lysosome-dependent p300/FOXP3 degradation and limits Treg cell functions and enhances targeted therapy against cancers. Exp Mol Pathol 2013 0.83
55 The TNF receptor superfamily: role in immune inflammation and bone formation. Immunol Res 2003 0.83
56 Test for detection of disease-associated prion aggregate in the blood of infected but asymptomatic animals. Clin Vaccine Immunol 2006 0.82
57 Efficiency of G2/M-related tumor-associated antigen-targeting cancer immunotherapy depends on antigen expression in the cancer stem-like population. Exp Mol Pathol 2011 0.82
58 The gefitinib-sensitizing mutant epidermal growth factor receptor enables transformation of a mouse fibroblast cell line. DNA Cell Biol 2006 0.82
59 HER2/Neu: mechanisms of dimerization/oligomerization. Oncogene 2002 0.81
60 Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism. Proc Natl Acad Sci U S A 2004 0.81
61 MDM2 regulates a novel form of incomplete neoplastic transformation of Theileria parva infected lymphocytes. Exp Mol Pathol 2012 0.79
62 Non-invasive, ultra-sensitive, high-throughput assays to quantify rare biomarkers in the blood. Methods 2008 0.79
63 A structural modulator of tumor necrosis factor type 1 receptor promotes bone formation under lipopolysaccharide-induced inflammation in a murine tooth extraction model. Eur J Pharmacol 2012 0.79
64 Modulation of biomolecular interactions with complex-binding small molecules. Methods 2008 0.78
65 Mutations in K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells. Exp Mol Pathol 2012 0.78
66 Therapeutic monoclonal antibodies for the ErbB family of receptor tyrosine kinases. Cancer Biol Ther 2003 0.78
67 Germinal center kinases in immune regulation. Cell Mol Immunol 2012 0.78
68 Molecular and biological role of the FOXP3 N-terminal domain in immune regulation by T regulatory/suppressor cells. Exp Mol Pathol 2012 0.78
69 Structure-based approaches to inhibition of erbB receptors with peptide mimetics. Immunol Res 2003 0.77
70 Towards comprehensive characterization of HER2 overexpression. Mol Syst Biol 2006 0.77
71 Structural aspects of the FOXP3 regulatory complex as an immunopharmacological target. Int Immunopharmacol 2009 0.77
72 The extracellular domain of p185(c-neu) induces density-dependent inhibition of cell growth in malignant mesothelioma cells and reduces growth of mesothelioma in vivo. DNA Cell Biol 2006 0.76
73 Reversion of the ErbB malignant phenotype and the DNA damage response. Exp Mol Pathol 2012 0.76
74 Differential localization of ErbB receptor ensembles influences their signaling in hippocampal neurons. DNA Cell Biol 2005 0.76
75 Structure based antibody-like peptidomimetics. Pharmaceuticals (Basel) 2012 0.76
76 Development of anti-EGF receptor peptidomimetics (AERP) as tumor imaging agent. Bioorg Med Chem Lett 2011 0.75
77 Trastuzumab in breast cancer. N Engl J Med 2006 0.75
78 Anergy and suppression as coexistent mechanisms for the maintenance of peripheral T cell tolerance. Immunol Res 2003 0.75
79 Mechanisms of peripheral immune tolerance: conversion of the immune to the unresponsive phenotype. Immunol Res 2003 0.75
80 Characterization of mouse tGolgin-1 (golgin-245/trans-golgi p230/256 kD golgin) and its upregulation during oligodendrocyte development. DNA Cell Biol 2002 0.75
81 FOXP3⁺ regulatory T cell development and function require histone/protein deacetylase 3. J Clin Invest 2015 0.75
82 Methods. Guest editor's introduction. Methods 2008 0.75
83 Regulation of the immune response. Curr Opin Immunol 2010 0.75